Keywords: Non-Hodgkin;s lymphoma, Combinationtherapy, Yttrium-90, Veltuzumab, Immunomedics

Potential new treatment regimen for non-Hodgkin lymphoma from Immunomedics

Article | 13 June 2012

US biopharmaceutical company Immunomedics (Nasdaq: IMMU) has reported initial clinical experience with a combination of epratuzumab, the Company's humanized anti-CD22 ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Immunomedics

Go to company listing

Related Drugs

veltuzumab

yttrium-90

Go to drug listing